PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, and the University of Massachusetts, have received a Phase I Small Business Technology Transfer (STTR) contract in the amount of $100,000 to support research to identify lead antimicrobial compounds to effectively treat multi-drug resistant and biofilm-embedded bacteria.
The sponsoring agency for this contract is the U.S. Army Research Office. The primary goal of the work funded by this Phase I STTR contract will be to develop select, targeted new derivatives of PolyMedix’s small molecule defensin mimetic antimicrobial compounds and identify lead molecules active against bacterial pathogens and their drug/multi-drug resistant strains that are often associated with biofilm infections. PolyMedix will receive $100,000 during this Phase 1 contract, to be disbursed over six months, with $35,600 of this total amount to be provided by PolyMedix to the University of Massachusetts Amherst in support of work to be done by Dr. Gregory Tew under the contract.